Background: Acetylcholinesterase (AChE) and amyloid precursor protein (APP) are implicated in Alzheimer's disease, but their specific biological roles remain unclear. Results: Overexpression or knockdown of neuronal APP modulates AChE mRNA, protein levels and activity. Conclusion: APP acts as a transcriptional regulator through a novel mechanism, independent of γ-secretase. Significance: Understanding the physiological functions of APP will lead to greater understanding of Alzheimer's disease aetiology.
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The amyloid precursor protein (APP) and acetylcholinesterase (AChE) are both multifaceted proteins with a wide range of functions. While they are both linked with growth and developmental processes, especially in the brain (1-3), they are also crucially linked with the pathogenesis of Alzheimer's disease (AD). APP is the precursor of the Aβ peptide, which is suggested to be the pathological agent in AD (4), with its oligomers considered the most toxic (5, 6) . AChE has also been linked to the disease pathogenesis by exacerbating amyloid fibril formation and toxicity (7) (8) (9) (10) and is the main target of clinically available AD drugs (11) .
AChE is a key protein in cholinergic signalling, of which there are several main systems in the brain. Among these, the basal forebrain cholinergic system (12) is strongly linked to AD (13) . There are reports specifically and consistently linking cholinergic hypofunction and cognitive decline. For reasons unknown, cholinergic neurons of the basal forebrain are specifically affected in AD (14) . The predominant neurotransmitter in this system is acetylcholine (ACh), which, like AChE, has been suggested to have trophic functions (15) .
The individual subunits of AChE can associate with each other, forming both dimers and tetramers. The Proline Rich Membrane Anchor (PRiMA) is a 20kDa protein responsible for both AChE tetramerisation and its anchorage to the membrane in neuronal cells. This is a crucial role as tetramers of AChE T form the functional units at cholinergic synapses (16) (17) (18) (19) . PRiMA has a Proline Rich Attachment Domain (PRAD), like its counterpart ColQ, which serves as a membrane anchor for AChE at neuromuscular junctions. The AChE-PRiMA association occurs between the C-terminal t peptides of AChE and the PRAD of PRiMA. It has also been suggested that disulphide bonds form between four Cys residues at the Nterminus of PRiMA and the C-terminal Cys in the AChE t peptide (17). Immunofluoresence studies have shown strong co-localisation between AChE and PRiMA in cholinergic neurons, but no localisation of PRiMA in either dopaminergic or GABAergic neurons (18).
APP is a type I integral membrane protein (see Fig. 1A ) (20) . It exists in three isoforms (APP 695 , APP 751 and APP 770 ), generated by differential splicing of exons 7 and 8 (21,22) . In terms of distribution, APP mRNA is expressed in almost every tissue, where only the isoform ratio differs (23) . It is APP 695 that predominates in neurons (2) and APP mRNA represents 0.2% of the total mRNA in these cells (24) . There are two proteolytic pathways of APP processing. Amyloidogenic processing is the minor pathway (approximately 5%) and involves sequential cleavage of APP by β-secretase and the γ-secretase complex, both aspartic proteases. These proteolytic events release Aβ and sAPPβ, with the former, although linked to AD, having physiological roles, such as ion channel regulation (25) . The second, non-amyloidogenic, pathway involves α-secretase cleavage of APP, which occurs within the Aβ region (26, 27) , precluding formation of Aβ, while generating a large, soluble ectodomain, the neuroprotective sAPPα (27) (28) (29) . Both pathways result in generation of the amyloid precursor protein intracellular domain (AICD), which can act as a transcriptional regulator (30) (31) (32) (33) (34) , although there remains some controversy about the precise cohort of genes involved in AICD-mediated transcriptional regulation (35) . Important residues in APP 695 for transcriptional regulation are Y682 and Y687, which represent the N-and C-terminal residues of the YENPTY motif in the cytoplasmic domain of APP (Fig. 1A) (36) . Functional AICD is mostly formed in the amyloidogenic pathway, predominantly from the APP 695 isoform (37) (38) (39) . Much of the transcriptional regulation by AICD is dependent on binding of the Fe65 protein, which may facilitate its nuclear translocation (40, 41) . Although the APP C-terminus is the predominant region for protein-protein interactions, other regions are also involved, e.g. via the extracellular E1 region with reelin (42), fibulin-1 (43) and integrin β1 (44, 45) and also in dimerisation of APP (46) . Within the E1 domain, there are subdomains, including the His-rich copper-binding domain (CuBD) (36, 47) , which has an important role in mediating APP dimerisation (48) .
The main goal of this study was to investigate whether APP 695 regulates AChE expression in neuronal cells. The concept of the cholinergic system regulating APP has been well documented (49, 50) but data about APP regulation of the cholinergic system are sparse. Here we show that overexpression, or, conversely, knockdown of APP 695 can modulate mRNA, protein and activity levels of AChE. In addition, PRiMA appears to be regulated via the same mechanism, while BChE and CHT remain unaffected. This novel mechanism is γ-secretase independent and is likely mediated via the E1 domain of APP, specifically the CuBD therein.
EXPERIMENTAL PROCEDURES
Cell culture. Cholinergic SN56 cells (kindly provided by Prof. A. Szutowicz, Medical University of Gdańsk, Poland) and GD25/ GD25β1 cells (a gift from Prof. S. Johansson, Uppsala University, Sweden) were cultured in DMEM (Lonza, Basel, Switzerland) and SH-SY5Y cells were cultured in DMEM F-12 (Lonza). All media were supplemented with 10% foetal bovine serum and 1% penicillin, streptomycin and L-glutamine. For SH-SY5Y cells, 1% non-essential amino acids were added. For transfected cells, either 150 µg/ml hygromycin B (wild type APP 695 or APP 695 with tyrosine/ histidine mutations) (Invitrogen, Paisley, UK) or 10 µg/ml blasticidin S (APP∆E1) (Invitrogen) was added. All cells were incubated at 37°C and 5% CO 2 in a humidified atmosphere.
Constructs. The APP 695 (pIRESHyg) construct was kindly provided by Dr. A. R. Whyteside (University of Leeds). APP 695 constructs expressing tyrosine mutations (all pIRESHyg: Y682G, Y687G and Y682G + Y687G double mutant) were prepared as follows. These APP Y682G and Y687G constructs were generated using site-directed mutagenesis to convert tyrosine codons (TAC) to glycine (GGC) according to the manufacturer's instructions (Agilent Technologies UK Ltd, Stockport, UK) using pIREShyg-wt-APP 695 as a template. The APP Y682G + Y687G double mutant was then generated in the same manner but using previously mutated APPY682G as a template. The APP∆CuBD (H147A, H149A, H151A triple mutant) was a kind gift from Dr. Edward Neale (Lancaster University, UK). The APP∆E1 (pLBCX, c-myc, 6xHis tag) was kindly provided by Prof. C. U. Pietrzik (Department of Pathobiochemistry, University Medical Center of the Johannes Gutenberg University, Mainz, Germany). Preparation of cell lysates for analysis of cellular proteins. Cells at ≥ 80% confluence or after pharmacological treatment as indicated above were washed twice in ice cold phosphatebuffered saline (PBS) and harvested in 10ml PBS. Cells were pelleted at 2700 x g for 5 min (4°C) and re-suspended in 6 x volume of lysis buffer (50mM Tris-HCl (pH 7.4) with 1% Triton X-100 and 0.5% sodium deoxycholate) with a 21G needle and syringe. Lysis was performed for 30 min on ice followed by centrifugation at 2700 x g for 5 min to clarify the lysates. Supernatants were collected for assays.
Preparation of cell media for the analysis of secreted proteins. Cells were washed with OptiMEM and incubated for 24h in OptiMEM. The cell medium was then collected and 5ml centrifuged (2400 x g, 5 min, 4°C) to remove cell debris. Media samples were then added to a 6ml 10kDa MWCO Spin X-UF 20 Concentrator (Corning Life Sciences, Amsterdam, The Netherlands). This was followed by centrifugation (2400 x g, 4°C) until the volume reached 0.75-1.0ml. At this point the media samples were centrifuged (10,000 x g, 10 min) in a new Eppendorf tube to clear cell debris.
Cholinesterase assay. This followed the classical method (51), modified as described before (52) . Absorbance changes were measured using a plate reader (412 nm) (Fluostar Omega, BMG LabTech, Aylesbury, Bucks, UK). Type IV AChE from Electrophorus electricus (diluted 1:12500) (Sigma Aldrich) was used as a positive control in the assays.
Determination of protein concentration. The BCA assay method was used for determining protein concentration and was performed as described by Smith et al (1985) . Both the bicinchoninic acid and 4% copper (II) pentahydrate solutions were supplied by Sigma Aldrich.
SDS-PAGE and Western
blotting. An 8% gel was used, unless otherwise stated. Protein samples (20-50µg) were run for 90 min (30mA and 300V) using a BioRad gel rig and Invitrogen PowerEase 500 power supply. Western blotting was performed as previously described (37) . Primary antibodies used were for AChE (AChE (C-16) sc-6430, goat, 1:250, Santa Cruz Biotechnology, CA, USA), APP (22C11, mouse, 1:2000, Millipore, Billerica, USA or anti-Cterminal fragment (CTF), rabbit, 1:1000, Sigma Aldrich), sAPPβ (rabbit, 1:250, Signet Laboratories) and β-actin (1:10000, mouse, Sigma Aldrich).
RT-PCR. RNA was isolated using the RNeasy kit (Qiagen), according to the manufacturer's instructions. cDNA was prepared using the iScript cDNA synthesis kit (BioRad, UK) and amplified using conventional PCR with Taq DNA polymerase (New England Biolabs, Hitchin, UK). Conditions were as follows: 94°C (5 min), 60°C (30s), 68°C (50s), for 35 cycles, then 68°C (10 min), using a PTC-200 Peltier Thermal Cycler (MJ Research, USA). Amplified DNA was resolved on 1% agarose gels with 50µg ethidium bromide and visualised on the Molecular Imager Gel Doc XR System with the Quantity One 4.6.1 programme (BioRad).
Primers (Sigma Aldrich) were for: APP-F:AAGAAGCCGATGATGACGAG; R:TTCTCATCCCCAGGTGTCTC and GAPDH-F:AACTTTGGCATTGTGGAAGG; R:CACATTGGGGGTAGGAACAC Quantitative PCR (qPCR). RNA was isolated and cDNA synthesised as above. Transcript levels were assessed using SensiMix SYBR Green (Bioline Reagents, London, UK) on a Rotor-Gene 6000 (Corbett Life Sciences, Cambridge, UK). Primers used were for human genes: AChE-F:TTCCTCCCCAAATTGCTCAG; R:TCCAGTGCACCATGTAGGAG PRiMA-F:TGATCATCATTGCCGTATGC; R:GGTGCCATTTTCGTCTTTTC Neprilysin-F:CCTGGAGATTCATAATGGATCTTG; R:AAAGGGCCTTGCGCAAAG and GAPDH-F:CAATGACCCCTTCATTGACC; R:GACAAGCTTCCCGTTCTCAG Primers used were for mouse genes: PRiMA-F:ATCATTGTCGCTGTGGTCTG; R:GGTGCCATTCTCATCCTTTC BChE-F:TTACAACCAAGACCGGAAGG; R:GTTGTGCATAGGGGATACCG CHT-F: ATATGGGCTGCATGGAAAAC; R: CACCAACCAACAAACCAATG U6-F:CTCGCTTCGGCAGCACA; R:AACGCTTCACGAATTTGCGT The AChE primers were used in both cell lines as they bind in a conserved area of the transcript.
siRNA knockdown. Wild type SN56 cells were transfected with either 25nM siRNA targeting APP (SmartPOOL, Dharmacon, Thermo Scientific) or a scrambled sequence (siRNA negative control, Ambion, Invitrogen) at an equivalent concentration using Lipofectamine (Invitrogen). The transfection medium was replaced with OptiMEM after 6-8h and cells harvested after 24h.
Statistical analysis. All statistical analysis was performed using an unpaired, 2-tailed Student's t-test (Microsoft Excel 2007). All error bars displayed are ± SEM. Statistical significance is defined as follows: p ≤ 0.05 (*), p ≤ 0.01 (**) or p ≤ 0.001 (***).
RESULTS

Overexpression of APP 695 in neuronal cell lines.
In order to investigate the possible regulation of AChE by APP, two neuronal cell lines, the human SH-SY5Y neuroblastoma cell line and the mouse cholinergic SN56 cell line were used. The SN56 cell line is a neuronal cell line derived from murine septal neurons of the basal forebrain (53) . A stable SH-SY5Y (APP 695 ) cell line had previously been generated and characterised (37) . We also generated a stable SN56 (APP 695 ) cell line which showed substantial increases in APP 695 protein (mature and immature) and also in mRNA transcripts as compared with mock-transfected cells (Fig. 1, B and C).
Analysis of AChE activity, protein and mRNA in transfected cell lines. AChE activity was assessed in cell lysates from both SN56 and SH-SY5Y cell lines (Fig. 2) . The activity was significantly reduced in cell lines stably overexpressing APP 695 compared to mock-transfected cells, by 75% in SN56 and by 40% in SH-SY5Y cells (Fig. 2, A and B ). This correlated with protein level changes caused by APP 695 overexpression as shown by Western blot analysis (Fig. 2, A and B, insets) . To assess the effects of APP 695 over-expression on AChE transcript levels, quantitative RT-PCR was used (Fig. 2, C  and D) . The results of mRNA analysis correlate with AChE activity and protein levels, with 95% reduction in AChE mRNA in SN56 (APP 695 ) cells and 50% mRNA reduction in SH-SY5Y (APP 695 ) cells. Furthermore, AChE activity was decreased in the medium of SN56 (APP 695 ) cells in proportion to the decrease seen in the lysates (data not shown).
Regulation of other cholinergic genes by APP 695
As catalytically active AChE is PRiMA bound (17), we investigated whether PRiMA expression was also changed with APP 695 overexpression, possibly either through co-regulation or in response to the significant decrease in AChE expression (Fig. 3A) . Quantitative PCR showed a significant 50% decrease in PRiMA transcripts in SN56 (APP 695 ) cells (p < 0.001). We further investigated the transcript levels of another cholinergic protein, namely BChE, which, however, showed no change with overexpression of APP 695 (Fig. 3B, p=0.51 ). To further expand our assessment of a more global regulatory effect by APP on the cholinergic system we again utilised qPCR to assay mRNA levels of the high-affinity choline transporter (CHT). We have confirmed expression of this protein in SH-SY5Y and SN56 cells by Western blot (data not shown). In SN56 cells overexpressing APP 695 , there were no changes in mRNA levels of CHT (Fig. 3C, p=0.99) .
Assessment of AChE mRNA levels after siRNAmediated knockdown of endogenous APP. After demonstrating the effects of APP overexpression on AChE mRNA levels and activity, we next examined the effects of knockdown of endogenous APP using siRNA. Transfection of wild type SN56 cells with a scrambled sequence oligonucleotide showed no effect on APP expression, but the APP-specific siRNA caused large reductions in APP protein levels (Fig. 3,  inset) . We then assessed AChE mRNA levels after siRNA knockdown of APP. Again, the scrambled sequence had no effect, but siRNA knockdown of APP resulted in a significant increase in transcription of AChE (Fig. 4) .
Investigation of the role of APP metabolites in
AChE regulation. We next examined the potential role of AICD in the APP-mediated regulation of AChE expression using the γ-secretase inhibitor, DAPT, to block AICD production (Fig. 5) . Inhibition of the γ-secretase complex precludes generation of AICD and upregulation of neprilysin (NEP) (33, 38) . Inhibition of AICD generation had no effect on total AChE activity in SH-SY5Y (APP 695 ) or SN56 (APP 695 ) cells (Fig. 5, A and B) . Furthermore, analysis of AChE mRNA levels by quantitative RT-PCR revealed no changes in these cell lines (Fig. 5, C and D) . Similarly, DAPT had no effect on AChE activity in wild type SN56 cells (data not shown). As with AChE, PRiMA mRNA transcripts showed no change on treatment with DAPT (data not shown). Successful inhibition of γ-secretase was confirmed by a significant reduction in transcript levels of the AICD-regulated gene, NEP (Fig.  5E) .
In order to assess the potential roles of the soluble ectodomains sAPPα and sAPPβ in the transcriptional repression of AChE, we went on to block their formation in SH-SY5Y (APP 695 ) and SN56 (APP 695 ) cells using the α-secretase inhibitor GM6001 and the β-secretase inhibitor β-IV. Neither of these inhibitors was able to alter cellular AChE activity in SH-SY5Y (APP 695 ) or SN56 (APP 695 ) cells (Fig. 6, A and  B) . Confirmation that the inhibitors were functional at the concentrations used was demonstrated by Western blot analysis for the APP ectodomains, sAPPα and sAPPβ, the production of which is dependent on α-secretase and β-secretase, respectively (Fig. 6C) .
Effects of mutagenesis of key residues and domains in APP 695 on AChE regulation . In order to elucidate the regions of APP which may be responsible for mediating transcriptional repression of AChE, we over-expressed three APP 695 mutant constructs in SN56 cells (Fig 7, A  and B) . Numerous interactions of proteins with APP are mediated through its C-terminal region (36) , the majority of which involve the YENTPY motif. The key residues therein, Y682 and Y687, were mutated, both individually and together. These mutations did not change the ability of APP to exert its repressive effects on AChE. When assessing both AChE activity and mRNA in these cell lines, we have found significant reductions after over-expression of the APP mutants (Fig. 7, C and D) . Although these APP constructs can undergo proteolysis in a slightly different manner compared to the wild type protein, we have already shown that proteolytically derived APP metabolites have no effect on AChE expression (Fig. 5 and 6 ), which would suggest that differential proteolysis would not have any effect on AChE.
Another region of APP which has several interacting partners is the extracellular E1 domain. To assess a possible role of this APP domain in transcriptional repression of APP, we expressed a deletion construct (APP∆E1) in SN56 cells (Fig. 7E) . Assessment of AChE activity and mRNA levels in these cells showed, in contrast to wild type APP 695 , no AChErepressing effect of the APP∆E1 construct (Fig.  7, F and G) . Similarly, expression of this construct did not result in any significant change in PRiMA mRNA levels (Fig. 7H) .
A significant reduction in AChE activity and mRNA levels was seen after transient transfection with the APP 695 construct (Fig. 8B  and C) . However, transient transfection of wild type SN56 cells with the APP∆E1 construct showed no change in AChE activity or mRNA levels compared with mock transfected cells ( Fig. 8E and F) , further supporting a role for the E1 domain in mediating AChE repression.
Effects of over-expression of APP 695 (∆CuBD)
The E1 domain has been linked to a number of APP-interacting proteins and also as containing critical residues in mediating APP dimerisation (36, 45, 46) . Indeed, studies of the APP interactome frequently list APP/APLP as an interacting partner for APP itself (54) . Therefore, we mutated a key motif in APP dimerisation and protein-protein interactions, the copper-binding domain (CuBD), mutating three critical His residues to Ala, generating APP 695 ∆CuBD. We over-expressed this APP construct in SN56 cells (Fig. 9A) to assess whether mutation of the CuBD would compromise the ability of APP to repress the transcription of AChE. These data showed the SN56 (APP∆CuBD) cells were unable to repress AChE activity in cell lysates (Fig 9B) . These findings were recapitulated at the mRNA level (Fig. 9C) .
Integrin β1 is not involved in mediating the transcriptional repression of AChE by APP 695
Integrins are transmembrane proteins with an intracellular NPXY motif, downstream of which intracellular signalling is better defined than any other candidate APP N-terminal ligands (44, 45) . We therefore investigated whether ITGB1 may be the transmembrane interacting partner of APP, through the C-terminal region of which intracellular signals are transduced. We used GD25 cells, which are null for ITGB1 (55) and their ITGB1-expressing counterparts, GD25β1.Transient transfection of both cell lines with wild type APP 695 resulted in non-significant decreases in AChE mRNA levels and there was no significant difference in the magnitude of this effect between GD25 and GD25β1 cells (data not shown).
DISCUSSION
Although full length APP has a number of putative functions, detailed investigation of these has been diverted by substantial focus on the amyloid hypothesis, dominated by Aβ (56) . Similarly, with AChE, attention has been diverted from investigation of its non-catalytic physiological roles. Although a protein with significant links with AD, AChE research has mostly focused on inhibition of its catalytic activity for therapeutic benefit, rather than understanding its physiology and metabolism in relation to the AD pathology. In order to elucidate any possible direct relationship between APP and AChE, the possible regulation of AChE expression by APP was investigated. Our data show that, in two different neuronal cell lines, SN56 and SH-SY5Y, APP 695 overexpression repressed expression of AChE. This negative regulation is occurring on a transcriptional level, with consequent reductions in AChE protein levels and enzyme activity. Although the data from our over-expression studies showed a clear relationship between the levels of APP and AChE expression and activity, we deemed it important also to investigate the effect of endogenous APP. Using siRNA, we were able to show that endogenous APP exerts a repressive effect on AChE transcription, showing that APP is a physiologically relevant modulator of AChE transcription.
Furthermore, it clearly demonstrates that our data are not artefacts of an over-expression system, with the relationship induced by large increases in protein translation. Some studies in vivo have reported changes in AChE activity when APP is overexpressed. A study by Van Dam et al., using the APP23 mouse model, showed a significant reduction in AChE activity in the basal forebrain, but not other regions examined (57) . A further study in APP23 mice observed moderate decreases in AChE activity, but also reported reductions in cholinergic fibre density (58) and Boncristiano et al. reported reduced neuronal volume in the basal forebrain of APP23 mice (59) . These data show that the degenerative phenotype in these AD model mice may be a confounding factor in the interpretation of AChE activity differences between wild type and transgenic mice.
We explored the possibility that APP had some pan-regulatory role in the cholinergic system, perhaps regulating a cohort of cholinergic genes, rather than one in particular. Apart from AChE, we have also found a regulatory relationship between APP and another cholinergic system protein, namely PRiMA, which, like AChE, was downregulated after APP 695 overexpression. This shows that, at least in this pathway, AChE and PRiMA levels are closely coupled. However, it is still unclear whether PRiMA is directly regulated by APP, or whether its downregulation is a consequence of modifications in AChE levels.
On the contrary, APP had no effect on another mammalian cholinesterase, BChE, since its levels were unchanged after APP 695 overexpression. Similarly, we were unable to find any effect on mRNA levels of the high affinity choline transporter, CHT. This suggests that the regulatory effects downstream of APP 695 overexpression exhibit some selectivity and specificity. Our data, then, argue against regulation of a subset of cholinergic genes by APP, with only AChE and its membrane anchor directly modulated.
In addition to APP itself, its metabolites have also been shown to exert biological effects (60, 61) . These metabolites include AICD, which regulates expression of numerous genes (61, 62) , as well as sAPPα and sAPPβ, whose mechanisms of action are still poorly understood (60) . Of the APP fragments, AICD is by far the best characterised as a transcriptional regulator (31, (61) (62) (63) . A large number of genes have been linked to AICD (64) , with some consistently shown to be upregulated, such as neprilysin (33, 34) and a much smaller number to be down-regulated, such as the epidermal growth factor receptor (EGFR) (65) .
However, the failure of a γ-secretase inhibitor to affect AChE mRNA or activity levels demonstrates that AICD does not regulate AChE in the mammalian neuronal cell lines used, with the repression of AChE expression unchanged by γ-secretase inhibition and hence ablation of AICD production. Since the effects of APP on AChE expression did not involve AICD, the possible involvement of the soluble APP ectodomains was also examined as they may have some roles in gene expression (60) . sAPPα has well reported neuroprotective and neurotrophic effects (23, 66) and there are data reporting an increase in neuronal survival and neurite outgrowth promoted by sAPPα in rat cortical neurons (23) . Further works have implicated enhancement of mitogenesis and synapse formation and stability as features of sAPPα action (67, 68) . Neuroprotective roles of sAPPα against glucose deprivation, glutamate toxicity and ischaemia were also reported (66, 69, 70) . Although there is scant evidence linking sAPPα to any specific genes, (60), sAPPβ has been linked to transcriptional regulation of transthyretin and Klotho (71) . However, despite such a range of physiological properties, we failed to observe any effect of inhibition of sAPPα or sAPPβ production on AChE activity.
The elimination of the major secretase-derived APP fragments (AICD, sAPPα and sAPPβ) as having a contributory role in repression of AChE transcription leaves full length APP as the most likely responsible species. It is not surprising that full length APP is involved in gene regulation, as it is linked to numerous signalling pathways and other processes (1,2). In terms of interactions of APP, the intracellular C-terminal region has the most documented interacting proteins, with key residues demonstrated to be Y682 and Y687, within the YENPTY motif (36) . However, our data demonstrate that mutation of these residues did not reduce the repressive effect exerted by APP and suggest that the observed transcriptional repression is unlikely to be mediated by the C-terminal region.
For further investigation of the role of APP in AChE repression, we have analysed the effect of deletion of the E1 region in APP. One possibility is that deletion of this domain prevents binding of an APP-interacting protein.
Several N-terminal APP binding partners have been reported, namely fibulin-1, reelin, Fspondin, Lingo-1, contactin 2, pancortins 1 and 3, integrin β1 (ITGB1) (36, 44, 45) . Of these, ITGB1 is capable of binding copper binding domains (72) , although this has not been directly shown for APP. A necessary requirement of a binding partner is that the interacting protein must be able to transduce intracellular signals which ultimately result in transcriptional repression of AChE. Most of the APP binding partners listed are adhesion proteins and many do not have any defined intracellular signalling activity. However, integrins do have defined intracellular signalling activity, modulating such proteins as focal adhesion kinase and Akt (73) . However, our studies have shown that, although ITGB1 is an interacting partner of APP, it is unlikely to be the N-terminal binding partner through which repression of AChE is transduced.
The data obtained in our work have clearly indicated that deletion of the E1 domain ablates the repressive activity of APP 695 , which suggests that this domain can mediate transcriptional repression of AChE. Previous studies have shown that the APP∆E1 construct traffics and localises in the same manner as wild type APP 695 (74) . We were able to characterise the CuBD within E1 as the region responsible for this transcriptional repression of AChE. This APP∆CuBD construct has been shown to traffic and undergo proteolysis in a manner very similar wild type APP 695 , although sAPPβ is reduced relative to wild type (Parkin et al., unpublished observations). Copper binding has been linked to promoting APP dimerisation (48) , but binding of interacting proteins to this region has also been suggested (75) and previous work has implicated integrins as being capable of binding CuBDs (72) . While ITGB1 does not appear to be the relevant interacting partner in the transduction mechanism, other interacting partners or even perturbation of dimerisation may be factors.
The data provide an insight into the relationship between APP and AChE and highlight a novel function for APP in regulation of gene expression independent of its intracellular domain. Although AD-linked genes have been shown to be regulated by APP, none of these regulatory pathways have been shown so far to involve the E1 domain of full length APP, although the holoprotein has been recently linked to regulation of cholesterol metabolism at a transcriptional level (76) . It is possible that repression of AChE serves to maintain cholinergic signalling by reducing ACh hydrolysis in a neurodegenerative environment. However, it is also possible that this relationship is independent of the catalytic function of AChE. AChE and APP both have roles in cell adhesion and synaptic integrity (3, 77) , so perhaps this novel relationship serves to regulate these noncatalytic functions. Finally, AChE has been shown to have a role in apoptosis, being upregulated by certain apoptotic stimuli and then participating in the process of apoptosis (78, 79) , including in AD (80) . As such this downregulation of AChE might be an example of a novel neuroprotective function of the APP holoprotein.
In order to elucidate any direct links between APP and the key cholinergic system proteins in mammalian cells, we have shown that APP 695 represses transcription of AChE in SH-SY5Y and SN56 cells. The mechanism is not dependent on APP metabolites produced by α-, β-, or γ-secretases, as their inhibition in cell culture does not ablate the effect of APP 695 overexpression. Furthermore, mutagenesis studies show that the C-terminal region of APP is unlikely to have any involvement in this process. However, the E1 region of APP appears to play a role in the transcriptional repression of APP. As current therapy focuses on inhibition of 
